{"name":"Blend Therapeutics","permalink":"blend-therapeutics","crunchbase_url":"http://www.crunchbase.com/company/blend-therapeutics","homepage_url":"http://www.blendtx.com","blog_url":"","blog_feed_url":"","twitter_username":"","category_code":null,"number_of_employees":null,"founded_year":null,"founded_month":null,"founded_day":null,"deadpooled_year":null,"deadpooled_month":null,"deadpooled_day":null,"deadpooled_url":null,"tag_list":"","alias_list":"","email_address":"info@blendtx.com","phone_number":"617-923-4100","description":"","created_at":"Mon Jan 09 03:55:54 UTC 2012","updated_at":"Mon Jan 09 04:01:54 UTC 2012","overview":"<p>Blend is discovering and developing integrative combination medicines with the unprecedented ability to precisely control each agent’s therapeutic action in concert. Using their proprietary Maestro™ platform, they design and integrate drugs to target distinct disease pathways with optimal efficacy and safety. Blend was founded by three leaders in the fields of chemistry and nanomedicine from MIT and Harvard Medical School: Dr. Robert Langer and Dr. Stephen Lippard of MIT, and Dr. Omid Farokhzad of Harvard Medical School. </p>","image":{"available_sizes":[[[150,58],"assets/images/resized/0016/9321/169321v1-max-150x150.jpg"],[[250,97],"assets/images/resized/0016/9321/169321v1-max-250x250.jpg"],[[266,104],"assets/images/resized/0016/9321/169321v1-max-450x450.jpg"]],"attribution":null},"products":[],"relationships":[],"competitions":[],"providerships":[],"total_money_raised":"$2.8M","funding_rounds":[{"round_code":"a","source_url":"http://www.biocentury.com/DailyNews/financial/2012-01-06/blend-debuts-with-28-million","source_description":"Blend debuts with $2.8 million","raised_amount":2800000,"raised_currency_code":"USD","funded_year":2012,"funded_month":1,"funded_day":6,"investments":[{"company":null,"financial_org":{"name":"Flagship Ventures","permalink":"flagship-ventures","image":{"available_sizes":[[[150,79],"assets/images/resized/0002/8188/28188v1-max-150x150.jpg"],[[250,131],"assets/images/resized/0002/8188/28188v1-max-250x250.jpg"],[[450,237],"assets/images/resized/0002/8188/28188v1-max-450x450.jpg"]],"attribution":null}},"person":null},{"company":null,"financial_org":{"name":"New Enterprise Associates","permalink":"new-enterprise-associates","image":{"available_sizes":[[[150,110],"assets/images/resized/0001/5083/15083v3-max-150x150.png"],[[150,110],"assets/images/resized/0001/5083/15083v3-max-250x250.png"],[[150,110],"assets/images/resized/0001/5083/15083v3-max-450x450.png"]],"attribution":null}},"person":null}]}],"investments":[],"acquisition":null,"acquisitions":[],"offices":[{"description":"","address1":"134 Coolidge Avenue","address2":"","zip_code":"02472","city":"Watertown","state_code":"MA","country_code":"USA","latitude":null,"longitude":null}],"milestones":[],"ipo":null,"video_embeds":[],"screenshots":[{"available_sizes":[[[150,112],"assets/images/resized/0016/9322/169322v1-max-150x150.jpg"],[[250,186],"assets/images/resized/0016/9322/169322v1-max-250x250.jpg"],[[450,336],"assets/images/resized/0016/9322/169322v1-max-450x450.jpg"]],"attribution":null}],"external_links":[]}